Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 35,667 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total value of $678,743.01. Following the sale, the president now owns 286,121 shares of the company’s stock, valued at approximately $5,444,882.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Craig A. Wheeler also recently made the following trade(s):

  • On Friday, September 1st, Craig A. Wheeler sold 20,367 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $17.00, for a total value of $346,239.00.
  • On Thursday, August 10th, Craig A. Wheeler sold 16,953 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.94, for a total value of $287,183.82.

Shares of Momenta Pharmaceuticals, Inc. (MNTA) opened at 17.50 on Wednesday. Momenta Pharmaceuticals, Inc. has a 52-week low of $10.75 and a 52-week high of $19.90. The stock’s market capitalization is $1.30 billion. The company has a 50-day moving average price of $16.86 and a 200-day moving average price of $15.82.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The company had revenue of $23.57 million during the quarter, compared to analyst estimates of $24.64 million. During the same period last year, the business earned ($0.31) EPS. Momenta Pharmaceuticals’s quarterly revenue was down 10.8% compared to the same quarter last year. On average, equities analysts anticipate that Momenta Pharmaceuticals, Inc. will post ($1.53) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Craig A. Wheeler Sells 35,667 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/craig-a-wheeler-sells-35667-shares-of-momenta-pharmaceuticals-inc-mnta-stock/1606645.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ameritas Investment Partners Inc. increased its stake in shares of Momenta Pharmaceuticals by 14.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 834 shares in the last quarter. Tortoise Investment Management LLC purchased a new position in shares of Momenta Pharmaceuticals during the second quarter valued at approximately $114,000. Pinebridge Investments L.P. lifted its holdings in shares of Momenta Pharmaceuticals by 4.3% during the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 363 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Momenta Pharmaceuticals during the first quarter valued at approximately $158,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of Momenta Pharmaceuticals by 13.3% during the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 1,570 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

A number of brokerages recently issued reports on MNTA. Stifel Nicolaus reiterated a “buy” rating on shares of Momenta Pharmaceuticals in a report on Wednesday. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. BidaskClub lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Maxim Group set a $6.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “sell” rating in a report on Thursday, August 3rd. Finally, Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a report on Thursday, September 28th. They set a “neutral” rating and a $18.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $16.78.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.